Producer
CSPC Pharmaceutical Group
Major Chinese pharmaceutical conglomerate with world-class fermentation infrastructure. Key producer of penicillin G, cephalosporin APIs, and 6-APA. Operates large bioreactors in Shandong and Hebei.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input CSPC Pharmaceutical Group supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something CSPC Pharmaceutical Group makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Antibiotic APIs (Penicillin G + Cephalosporins)
35%Finished Pharmaceutical Products (China Domestic)
40%Oncology & Innovative Drugs (Emerging)
25%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
CSPC's dual structure — commodity antibiotic APIs (penicillin G, 6-APA, cephalosporins) AND innovative oncology/neurology drug development — represents two diametrically opposite pharmaceutical business models operating from the same Hebei Province company: (1) Commodity APIs — high volume, low margin, competing on cost against other Chinese producers; serves as the supply chain for global generic amoxicillin and cephalosporins that hospitals depend on; subject to Chinese export controls and procurement practices; (2) Innovative drugs — low volume, high margin, competing on efficacy, safety, and IP protection; requires proprietary clinical trial data and regulatory exclusivity. The same CSPC corporate parent: supplies amoxicillin that costs USD 0.05/dose to hospitals globally AND is developing BTK inhibitors that could cost USD 10,000+/month for cancer patients. The economics of these two businesses are inversely correlated — commodity antibiotic price pressure benefits from China's scale, while innovative drug value accrues from exclusivity. CSPC's hope is that the commodity business pays for the R&D that builds the innovative business that eventually replaces the commodity business.
CSPC Pharmaceutical Group Limited ↗Origin2023
CSPC Pharmaceutical Group represents the strategic evolution that NCPC and similar Chinese API manufacturers are attempting: using commoditized antibiotic API manufacturing as a cash flow base to fund proprietary drug development. CSPC is HKEX-listed (1093.HK) — an important distinction from state-owned NCPC; public listing on Hong Kong Stock Exchange gives CSPC access to international institutional capital, required for funding drug development pipelines costing hundreds of millions of dollars. The company's NBP (dl-3-butylphthalide) stroke treatment product — developed by CSPC's R&D team and marketed in China — represents the prototype of a Chinese pharmaceutical company building proprietary branded drugs from an API foundation. The transition is constrained by the same economics that constrain all API-to-innovative transitions: antibiotic API margins are low and under constant pricing pressure from new Chinese competitors; innovative drug R&D requires 10-15 years and billions in investment; the cash flow from one barely supports the other. CSPC is attempting to bridge this gap by licensing its innovative candidates to global pharma for milestone and royalty income while maintaining its commodity API base.
CSPC Pharmaceutical Group Limited ↗